Camptothecin
possesses broad antitumor spectra on various cancers.
In spite of its marked tumor-suppressing potency, camptothecin is
too hydrophobic to be solved in water and therefore not currently
in clinical use. CPT-11 (irinotecan) is one of the hydrophilic analogues
of camptothecin and widely prescribed. However, its water solubility
is still low and furthermore evokes severe diarrhea. Therefore, we
designed and synthesized novel highly hydrophilic camptothecin derivatives
by conjugating SN38 with branched glycerol trimer (SN38-BGL), which
we have been developing as a unique strategy to endow hydrophobic
molecule with much hydrophilicity, to maximize the benefit of CPT-11
and minimize the adverse effects. The SN38-BGLs exhibited equivalent
or slightly stronger tumor-suppressing effects in murine xenograft
human lung cancer models compared to CPT-11. However, neither early-
nor late-onset diarrhea was observed when SN38-BGL was administered.
Heights of villi in jejunum and ileum were bigger than those from
CPT-11-treated mice, indicating that SN38-BGL is less harmful than
CPT-11. Ex vivo digestion by liver microsome did not yield SN38 but
a couple of other molecules against our expectations, which suggests
the involvement of other active metabolites than SN38 and may explain
the differences. Hence, SN38-BGLs can be a novel hydrophilic camptothecin
derivative without causing severe diarrhea.